Chaitanya Sudrik

Director, Formulation Development at Elektrofi

Chaitanya Sudrik has worked in various roles across different companies. In 2018, they worked at Elektrofi as an Associate Director, Principal Scientist, and Sr. Scientist. In this role, they led the prioritization and planning of research projects, managed research staff, developed platform formulation screening and optimization workflows, and conducted research investigations to identify process and formulation variables. From 2015 to 2018, they worked at the Massachusetts Institute of Technology (MIT) as a Postdoctoral Associate where they characterized the preferential interactions of commonly used excipients with monoclonal antibody (mAb) surface. From 2009 to 2015, they worked at Rensselaer Polytechnic Institute as a Postdoctoral Research Associate, Graduate Research Assistant, and Teaching Assistant. As a Postdoctoral Research Associate, they engineered a light-sensitive plant protein to study protein aggregation inside live cells. As a Graduate Research Assistant, they developed a cis-regulatory mRNA element to tune recombinant protein production in mammalian cells. As a Teaching Assistant, they mentored a class of undergraduate students on design projects and homework problems. In 2008, they worked as a Summer Intern at LANXESS where they designed a packed bed scrubber to reduce emission of toluene and conducted process integration resulting in a 3-fold decrease in column height.

Chaitanya Sudrik obtained their Bachelor of Science in Chemical Engineering from the Institute of Chemical Technology, Mumbai in 2009. Chaitanya then went on to pursue a Doctor of Philosophy in Chemical and Biological Engineering from Rensselaer Polytechnic Institute, which they completed in 2014.

Location

Cambridge, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Elektrofi

1 followers

Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company’s founding team of MIT engineers and scientists are shaping the future of biologics delivery.


Industries

Employees

11-50

Links